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A B S T R A C T
Purpose: Various factors may affect intrauterine foetal growth, amongst which conditions such as
epilepsy and the use of anti-epileptic drugs (AED) may play a role. This study investigated intrauterine
growth of foetuses in women with epilepsy, as compared with controls, and explored whether
intrauterine growth was affected by prenatal exposure to AED.
Method: Data were obtained from prospectively registered data regarding pregnancy and prenatal and
perinatal factors in women in Oppland County in Norway. The ﬁnal analysis included information from
166 mothers with epilepsy and 287 children. The control group consisted of 40,553 pregnancies in
women without epilepsy registered in the same database.
Results: There was a signiﬁcantly higher risk of the ponderal index being below the 10th percentile and
infants being small for gestational age (SGA) in the epilepsy group; exposure to AED increased the risk.
The frequency of SGA and low ponderal index was highest in Lamotrigine exposed infants. In the AED
group, head circumference was signiﬁcantly smaller among Carbamazepine exposed.
Conclusion: Impaired intrauterine growth of foetuses in women with epilepsy was identiﬁed. The
frequency of SGA and low ponderal index was highest in Lamotrigine exposed infants. The epilepsy
group had a higher risk proﬁle for having smaller babies, in being younger at age, lower in body weight
and more frequent smokers. However despite these differences, the effects of epilepsy and AED exposure
were signiﬁcant. The ponderal index may be a useful supplement to more established measures
assessing intrauterine growth in epilepsy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Maternal health, diet, medication, smoking habits, placenta
function, and genetic factors have all been assumed to affect
intrauterine foetal growth. Limited data suggest that intrauterine
growth in foetuses is decreased in women with epilepsy [1,2,3]. Low
birth weight, reduced head circumference, and increased risk of
being small for gestational age (SGA) have been associated with
epilepsy, and in particular exposure to anti-epileptic drugs (AED) in
pregnancy [2,4,5]. In some recent studies, increased rates of* Corresponding author at: Innlandet Hospital Trust, A. Sandvigsgt 17, 2609
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exposed to carbamazepine (CBZ), topiramate and AED polytherapy
in utero [2,6,7]. Veiby et al. [7] reported a signiﬁcantly increased
risk of SGA < 10 percentile in infants born to mothers with epilepsy.
This applied not only to mothers using AED, but also women
with epilepsy not using AED. A recent study based on Danish
Medical Birth Registry data (Kilic et al., 2014) found AED exposure
associated with lower birth weight and increased risk of SGA among
children of mothers with epilepsy, whereas AEDs were associated
with increased risk of preterm birth only among mothers with-
out epilepsy. On the other hand, small head circumference was
associated with AED exposure only among children of mothers with
epilepsy [2]. The mechanisms behind the apparent reduction in
intrauterine growth have not been identiﬁed. The Norwegian part of
the EURAP study, a multinational registry of women using AEDs inserved.
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the group of 296 AED exposed infants [8]. These observations
highlight the importance of taking into account maternal factors e.g.
the indication for treatment, and this is unfortunately where
registers with un-validated epilepsy diagnoses may fall short.
Another factor in intra uterine growth is the maternal weight before
and during pregnancy, a factor that has not been controlled for in
recent studies [2,7].
An estimation of gestational age depends upon provision of a
reliable date of last menstruation. Women with epilepsy may have
more cycle disturbances [9] than women without epilepsy, thus
determination of true gestational age, and thereby also SGA, may
be difﬁcult. Small parents and genetic variations in growth must
also be taken into account. Furthermore, SGA and birth weight are
also inﬂuenced by the mother’s weight or body mass index (BMI).
The ponderal index (kg/m3), however, is less dependent on
gestational age and parental size, and thus has the potential of
providing more accurate information [10]. In Norway, all pregnant
women are offered a routine ultrasound investigation at gesta-
tional week 17 or 18. The estimated date of delivery (EDD) can be
estimated based on these ultrasound measurements. Small
measurements at this time point will indicate a later EDD,
whereas large measurements indicate an earlier EDD. Thus, early
intrauterine growth restriction on a group level would result in
negative difference between the EDD based on the Naegele’s
rule (date for most recent menstruations last day + 7 days 
3months + 1 year) and the EDD based on ultrasound measure-
ments.
The purpose of this study was to assess intrauterine growth of
foetuses in women with epilepsy as compared with intrauterine
growth in controls and where unlike previous register studies the
epilepsy diagnoses has been validated and classiﬁed. Furthermore,
we wanted to explore whether intrauterine growth restriction
(IUGR) was associated with prenatal exposure to AED.
2. Material and methods
2.1. Data source
This study was based on prospectively registered data
regarding pregnancy and prenatal and perinatal factors in women
in Oppland County in Norway.Fig. 1. EpilepsThe Oppland Perinatal Database (OPD) contains prospectively
registered information on all pregnant women who gave birth at
one of the two obstetric departments in Oppland County during
the period from 1989 to 2012, and includes information on 43,490
pregnancies and births. The OPD information is derived from
approximately 95% of all pregnant women in the county during the
relevant period. The women with active epilepsy were mainly
investigated and followed up by neurologists at the same hospital,
and medical records were shared. The cohort includes all births of
residents in the county, except for very preterm births and
approximately 50 births annually that occurred outside the
county. In addition, approximately 200 births per year are included
from a large municipality of a neighbouring county.
Demographic and medical information, as well as information on
smoking and alcohol habits, were systematically collected in
conjunction with the routine ultrasound examination (week 17–
19), at birth, and also if the woman was monitored for medical
reasons at the obstetric departments in the interim period. Data
regarding the women’s health, including chronic illness, were
registered in a standard pregnancy health record, and added to
the OPD at delivery. Pregnancy records reporting epilepsy were
registered in OPD as chronic illness and speciﬁed epilepsy.
2.2. Inclusion of mothers with epilepsy
All women in OPD with a validated diagnosis of epilepsy at one
point in their lives were included in this study. The women received
a letter with information on the study and the option to exclude
themselves from participation, according to the Health Research Act
§35. Epilepsy was registered in a total of 346 pregnancies. After
validation of all diagnoses, there were 303 pregnancies by
173 women with validated active or earlier epilepsy. Women
without a validated diagnosis or ongoing drug abuse were excluded
from further analysis. Seven women did not wish to be included in
the study, and thus 166 mothers of 287 children were eligible for the
ﬁnal analysis. The epilepsy diagnosis was validated by a neurologist
(AHF) according to the International League Against Epilepsy (ILAE)
criteria and by evaluation of medical records and EEG-descriptions.
Epilepsy classiﬁcation was carried out by three independent
neurologists (KON, ML, AHF). Among the 287 pregnancies included
in the study, 165 were by mothers with focal epilepsy, 83 by mothers
with generalized epilepsy, and 39 by mothers with unclassiﬁable
epilepsy (Fig. 1, Table 1). Pregnancies in women without epilepsyy group.
Table 1
Epilepsy group characteristics.
Focal, n (%) Generalized, n (%) Unclassiﬁed, n (%) Total
Women 96 (57) 47 (28) 23 (14) 166
Number of pregnancies, n (% of total in epilepsy group) 165 (57.5) 83 (29) 39 (13.5) 287
AED during pregnancy (%) 91/165 (55) 59/83 (71.1) 9/39 (23) 159
CBZ 43/91 (47) 16/59 (27) 2/9 (22) 61
VPA 9/91 (10) 19/59 (32) 3/9 (33) 31
LTG 13/91 (14) 10/59 (17) 0/9 (0) 23
Polytherapy 12/91 (13) 10/59 (17) 2/9 (22) 22
Other (LEV: 5, TPM: 3) 14/91 (15) 4 (7) 2/9 (22) 18
CBZ, carbamazepine; VPA, valproate; LTG, lamotrigine; LEV, levetiracetam; TPM, topiramate.
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were used throughout the pregnancy (Fig. 1). For 12 pregnancies,
AEDs were discontinued by week 12, and these were classiﬁed as
‘‘untreated’’.
3. Statistics
The statistical analyses were performed using SPSS 18. Possible
group differences were tested using the Pearsons’s Chi square test
and independent sample t test for categorical and continuous data,
respectively. All tests were two-sided and were performed at a 5%
signiﬁcance level. Odds ratios (OR) for reduced intrauterine growth
were estimated with the corresponding 95% conﬁdence intervals
(CI) and p values using logistic regression analysis, with low
ponderal index and SGA as dependent variables respectively, and
epilepsy, AED, smoking, BMI (body mass index), psychiatric co
morbidity and drug abuse as the independent variables. Missing
data in the analysis are due to failure of registry at time of registry
into the OPD.
4. Results
Basic characteristics of the total epilepsy group and the sub
groups using AED and not using AED were compared to controls
(Table 2). Mean age and age at ﬁrst registered birth was
signiﬁcantly younger in the epilepsy group. The mothers’ BMI
before pregnancy was signiﬁcantly lower in the women with
epilepsy than in the controls. Mean weight gain during pregnancy
was approximately the same in both groups, and there was no
difference in mean height between women with epilepsy and
without epilepsy (data not shown). There were small, but
signiﬁcant, differences between the two groups regarding smoking
habits at time of conception and substance abuse.
4.1. Ponderal index
There was a signiﬁcantly higher risk of the ponderal index being
below the 10th percentile (16.0% vs 11.9%, p = 0.027) (ponderal
index percentiles derived from the total OPD material) and SGA
below 10th percentile (10.6% vs 7.5%, p = 0.040) in the epilepsyTable 2
Basic characteristics of the total epilepsy group and subgroups (AED and No AED) com
Controls n = 40,553 WWE n = 287 
Mean age (y) 28.8 27.8 
Age at ﬁrst registered birth (y) 27.8 26.4 
Smoking at time of conception (%) 24.3 34.0 
Smoking at 18 weeks (%) 19.7 20.6 
Smoking at time of partus (%) 14.9 15.0 
Psychiatric illness (%) 1.9 2.7 
Substance abuse (%) 0.2 0.7 
BMI < 18.5 (%) 3.2 6.1 
AED, antiepileptic drug; WWE, women with epilepsy; BMI, body mass index.group [11], and exposure to AED increased the risk of low ponderal
index (Table 3). 19% of lamotrigine exposed versus 11.9% of the
controls had ponderal index below the 10 percentile (p = 0.31).
Mean ponderal index was signiﬁcantly lower both in the total
epilepsy group and the subgroups of AED exposed and unexposed.
Controlling for siblings by analysing only for the ﬁrst registered
child demonstrated the same trend (data not shown).
AED exposure was the strongest predictor for low ponderal
index in univariate and multivariate analysis, with odds ratio (OR)
of 1.76 (p < 0.01, CI 2.6–1.2) and OR 1.86 (p = 0.02, CI 3.12–1.08)
respectively, controlling for smoking, BMI prior to pregnancy,
drugs and psychiatric co morbidity (Table 4). Controlling for
low BMI in the mothers did not signiﬁcantly alter the estimated
risk.
4.2. SGA
Infants of mothers with epilepsy had a signiﬁcant elevated risk
of SGA (Table 3), and in particular the CBZ exposed infants (14.8%
vs 7.5%, p = 0.03). The LTG exposed group had a nearly signiﬁcant
elevated risk (18.2% vs 7.5%, p = 0.056) (Table 3), i.e. four out of
22 Lamotrigine-exposed newborns had SGA below the 10 percen-
tile. The risk of SGA and ponderal index in the non-exposed
epilepsy group was just slightly increased (Table 3).
There was a signiﬁcantly lower mean BMI in mothers with
epilepsy (Table 2). Low BMI and drug abuse were more strongly
associated with SGA being below 10 percentile with OR 2.44
(p < 0.001, CI 1.95–3.06) and 3.63 (p < 0.001 CI 2.17–6.06) in
univariate and OR 2.23 (p < 0.001, CI 1.72–2.81) and 2.32
(p < 0.01 CI 1.23–4.20) in multivariate analysis respectively
(Table 4).
4.3. Birth weight and head circumference
Mean birth weight was signiﬁcantly lower in the total epilepsy
group (mean difference: 79 g, p = 0.029). Although the mean birth
weight in infants from mothers with untreated epilepsy was lower
than in infants in the control group, the head circumference was
not signiﬁcantly smaller in this group. In the AED-exposed group
and in particular the CBZ-exposed infants, head circumference waspared to the controls (women without epilepsy).
p AED n = 158 p No AED n = 129 p
0.001 27.8 0.02 27.6 0.02
<0.001 27.8 0.02 26.0 <0.01
0.001 36.3 <0.01 31.4 0.10
0.11 22.9 0.33 18.0 0.65
0.97 16.4 0.66 13.4 0.68
0.31 0.6 0.24 5.2 0.01
0.08 0.6 0.24 0.7 0.17
0.03 4.9 0.35 7.4 0.02
Table 3
Group differences in chi-square and independent t-test between total epilepsy cohort, epilepsy group on AED and on different AED compared with controls.
Controls
n = 40,553
Epilepsy
n = 287
p AED
n = 158
p No AED
n = 130
p CBZ
n = 61
p VPA
n = 31
p LTG
n = 23
p
SGA < 10 percentile (%) 7.5 10.6 0.04 12.7 0.012 8.2 0.74 14.8 0.03 6.5 0.83 18.2 0.056
PI < 10 percentile (%) 11.9 16.0 0.03 18.6 0.01 13.8 0.49 14.3 0.58 14.3 0.70 19.0 0.31
PI, mean (kg/m3) 27.5 26.9 <0.001 26.9 0.01 26.8 <0.01 27.2 0.46 26.9 0.24 27.1 0.49
Birth weight (g) 3528.8 3449.8 0.03 3433.5 0.05 3462.3 0.22 3423.4 0.18 3416.7 0.31 3369.3 0.22
Head circumference 35.3 35.0 0.01 35.0 0.03 35.1 0.17 34.7 0.01 34.9 0.29 35.4 0.65
Placenta weight 703.6 676.5 0.02 679.9 0.13 672.8 0.06 691.7 0.66 712.9 0.78 666.0 0.32
BMI at start of
pregnancy
24.92 23.99 0.008 24.13 0.11 23.8 0.032 23.44 0.09 24.07 0.44 22.9 0.05
Weight at start of
pregnancy
69.91 67.38 0.015 68.21 0.243 66.5 0.022 66.59 0.203 67.2 0.407 65.7 0.16
Weight at end of
pregnancy
83.43 80.45 0.005 81.7 0.255 79.1 0.004 80.50 0.274 80.05 0.315 78.6 0.12
SGA, small for gestational age, percentiles from Skjærven et al.; PI, ponderal index (kg/m3); BMI, body mass index; AED, anti epileptic drugs; CBZ, carbamazepine; VPA,
valproate; LTG, lamotrigine; No AED, women with no anti epileptic drug treatment; including no medication since childhood or ever, during pregnancy or who stopped taking
the medicine within week 12 of pregnancy.
Table 4
Odds ratios (OR) and 95% conﬁdence intervals (CI) for intrauterine growth restriction using univariate and multivariate logistic regression analysis in AED exposed and the
total epilepsy group respectively.
Univariate Multivariate
OR CI p OR CI p
Low ponderal index
Epilepsy + AED 1.76 2.63–1.16 <0.01 1.86 3.12–1.08 0.02
Smoking at time of conception 1.08 1.19–0.98 0.11
BMI < 18 1.42 1.79–1.12 <0.01 1.42 1.79–1.12 <0.01
Psychiatric co morbidity 1.25 1.02–0.63 0.07
Drug abuse 1.46 2.65–0.80 0.21
SGA < 10 percentile
Epilepsy + AED 1.90 1.20–3.01 <0.01 1.86 1.04–3.31 0.04
Smoking at time of conception 2.06 1.85–2.28 <0.001 2.06 1.82–2.32 <0.001
BMI < 18 2.44 1.95–3.06 <0.001 2.23 1.79–2.82 <0.001
Psychiatric co morbidity 1.27 0.99–1.62 0.06
Drug abuse 3.63 2.17–6.06 0.005 2.32 1.28–4.21 0.005
Low ponderal index <
Epilepsy 1.45 2.00–1.00 0.02 1.52 2.28–1.00 0.05
Smoking at time of conception 1.08 1.19–0.85 0.11 1.07 1.20–0.95 024
BMI < 18 1.42 1.80–1.12 <0.01 1.43 1.81–1.13 <0.01
Psychiatric co morbidity 1.25 1.02–0.62 0.07 1.41 1.05–1.89 0.22
Drug abuse 1.46 2.64–0.80 0.21 1.01 2.28– 0.46- 0.86
SGA < 10 percentile
Epilepsy 1.48 1.02–2.15 0.04 1.41 0.89–2.24 0.15
Smoking at time of conception 2.06 1.85–2.28 <0.0001 2.06 1.83–2.33 <0.0001
BMI < 18 2.44 1.95–3.06 <0.0001 2.23 1.77–2.81 <0.0001
Psychiatric co morbidity 1.27 0.99–1.62 0.06
Drug abuse 3.63 2.17–6.06 <0.0001 2.32 1.23–4.20 <0.01
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weight was slightly lower in the epilepsy group than in the controls
(Table 3).
In this study, the newer AED (topiramate, levetiracetam) were
only used as monotherapy in a small number of pregnancies
(Table 1). However, topiramate-exposed newborns demonstrated
the lowest values for mean head circumference (33 cm, mean
difference 2.3 cm) and birth weight (2926.7 g, mean difference
602.1 g) in the total epilepsy group. Two out of three topiramate-
exposed newborns had SGA below the10 percentile (p < 0.0005).
Levetiracetam-exposed newborns had higher values for ponderal
index, ultrasound measurements, birth weight, and head circum-
ference, but the differences were not signiﬁcant.
The ultrasound measurements were generally smaller in the
epilepsy group than among the controls, and signiﬁcantly lower in
the untreated epilepsy group (data not shown). When controlling
for the difference between ultrasound EED and Naegele EED, no
signiﬁcant differences were identiﬁed.5. Discussion
The main ﬁnding from this study is that the risk for SGA and
ponderal index being below the 10 percentile was signiﬁcantly higher
in the epilepsy group than in the controls. In particular, newborns
exposed to CBZ during pregnancy had a signiﬁcantly higher risk of
SGA being below 10 percentile and a smaller head circumference.
However, it needs to be emphasized that statistical analysis of
association with other AEDs is hampered by the considerable fewer
exposures. In fact, the proportion of exposed infants with SGA < 10
and ponderal index < 10 with LTG was higher than with CBZ (18.2%
vs. 14.8%, and 19.0% vs 14.3%, respectively). Additionally, LTG was
associated with the lowest BMI and body weight in the mother, in
addition to the lowest mean birth weight and placenta weight. The
explanation for the growth restrictions is unclear, but is likely to be
multi-factorial. More infants in the control group had a risk of low
ponderal index than SGA, indicating that ponderal index may be a
sensitive measure of intrauterine growth restriction.
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the controls. Reduced placenta weight may indicate placenta
dysfunction, which may lead to reduced growth of the foetus. A
previous Norwegian study reported a tendency towards smaller
birth weight in children of mothers with epilepsy not using AED
[4], while the frequencies of placental disorders were not
increased. However, low BMI before pregnancy may predispose
for small placenta weight and, thus, smaller infants.
In the current study, BMI and bodyweight at the start, during, and
end of pregnancy, were signiﬁcantly lower in the epilepsy group
than in the controls. This was an unexpected ﬁnding. Possible
explanations may be that women with epilepsy may be more
conscious of their weight because of warnings regarding AED being
associated with weight-gain. Alternatively, among the female
epilepsy population, those that are child bearing may be more
active, and thus have a lower BMI, than other people with epilepsy.
Eating disorders and depression have been found at increased rates
in untreated epilepsy before pregnancy [12]. Also, weight before
pregnancy was registered in the pregnancy record and was partly
self-reported, thus reporting bias cannot be ruled out.
Although smoking was more common in women with epilepsy
at the beginning of the pregnancy, at 18 weeks the deviation from
the controls in this respect was modest. Studies have indicated that
smoking early in pregnancy does not have such an impact on foetal
growth as smoking later in pregnancy, when the oxygen demand
over the placenta is more profound [13]. However, smoking and
the mothers’ BMI may be confounding variables inﬂuencing the
placenta weight and function, particularly in the last part of the
pregnancy. Substance abuse was more common among the women
with epilepsy, though not signiﬁcant (Table 2). Only one person
was noted having an ongoing drug abuse during pregnancy and she
was excluded from analyses. The frequency of psychiatric illness
was lower than expected in the epilepsy group, possible due to
the registry format of data, in which only established psychiatric
diagnoses were included and there was no registry-speciﬁc
screening for psychiatric symptoms.
The mean ultrasound measurements were signiﬁcantly smaller
in children of women with epilepsy, and in both sub groups (AED or
no AED) (data not shown). However, there was no signiﬁcant
difference between the Naegele EED and ultrasound EED, and
therefore the ultrasound measurements in week 17–18 do not
necessarily indicate an early restriction in growth. It is rather
possible that the smaller ultrasound measurements reﬂect the
tendency towards early referral to ultrasound in higher risk
pregnancies and the signiﬁcant lower BMI in the mothers.
Many studies of intrauterine growth in women with epilepsy
are based on register data. Such studies have important limitations
as the epilepsy diagnoses and epilepsy classiﬁcation are rarely
validated, and the data on AED treatment is usually restricted. In
the current study, the epilepsy diagnoses were validated and the
epilepsies classiﬁed.
The clinical importance of intrauterine growth restriction
associated with epilepsy is undecided. In general, foetal growth
is strongly associated with pregnancy outcome. When studied as a
single group, infants with intrauterine growth restriction, irre-
spective of cause, have increased mortality and morbidity [10]. The
differences in ponderal index, birth weight and SGA in this
study were mostly small, but signiﬁcant and in line with other
studies [2,6,7]. However, to evaluate whether growth restrictions
in infants of mothers with epilepsy are associated with later
morbidity or neurocognitive deﬁciencies, more studies with
extensive follow up are required.6. Conclusion
The impaired intrauterine growth of foetuses in women with
epilepsy found in this study was statistical signiﬁcant, but the
clinical importance of these ﬁndings are to be studied further. The
epilepsy group had a higher risk proﬁle for having smaller babies,
in being younger at age, lower in body weight and more frequent
smokers. However despite these differences, the effects of epilepsy
and AED exposure were signiﬁcant. CBZ was the most frequently
used AED, and the only AED that was signiﬁcantly associated with
smaller babies, but the frequency of low SGA and ponderal index
was in fact higher in LTG exposed infants. The ponderal index may
be a useful supplement to more established measures assessing
intrauterine growth in epilepsy.
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